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1. Introduction  
Routine monitoring of body iron stores is an essential component of the management of 
patients with end-stage renal disease (ESRD) receiving chronic hemodialysis treatment 
(CHD). Maintenance of adequate iron stores is important for the prevention of iron overload 
as well as for the treatment of iron deficiency and anemia, and this goal is generally 
achieved by intravenous iron administration. Despite regular iron supplementation, anemia 
due to renal failure, blood losses related to the procedure, and chronic inflammation is a 
typical finding in CHD patients, and is associated with increased mortality, reduced 
physical and mental function, and poor quality of life. Treatment often requires the 
administration of erythropoiesis stimulating agents (ESAs), but many patients do not 
respond adequately and/or require high doses of these medications, with potential adverse 
cardiovascular and infective events.  
A correct iron balance is required for the functionality of catalytic enzymes and proteins 
crucial for DNA synthesis, transport and storage of oxygen via hemoglobin and myoglobin, 
transport of electrons and cell respiration, oxidative phosphorylation, tricarboxylic acid 
cycle, and many other biochemical pathways. On the other hand, excess free iron is toxic to 
the cells due to its ability to catalyze free radical generation. Therefore, specialized transport 
systems and membrane carriers have evolved to keep iron in a soluble state that is suitable 
for circulation into the blood and transfer across cell membranes. Additionally, the absence 
of a physiological excretion mechanism requires systemic iron homeostasis to be regulated 
by intestinal absorption and iron recycling from erythrophagocytosis of senescent red cells.  
Iron metabolism is frequently altered in CHD due to decreased saturation of transferrin (TF), 
the plasma iron carrier, resulting in reduced iron availability for erythropoiesis, because of 
chronic inflammation and/or blood losses. Furthermore, inflammation and oxidative stress 
induce iron retention in macrophages and the transcription of ferritin, a protein with anti-
oxidant activity, and hyperferritinemia indicating increased iron stores, and chronic 
inflammation is frequently observed in these patients. Hyperferritinemia, reflecting iron 
overload, oxidative stress, and genetic factors, is associated with imminent death risk, mainly 
related to cardiovascular events, the leading cause of death in these subjects.  
www.intechopen.com
 Hemodialysis - Different Aspects 
 
140 
A major breakthrough in our understanding of iron metabolism has been the discovery that 
hepcidin, a peptide secreted by the liver in response to excess iron, inhibits intestinal iron 
absorption and iron recycling from monocytes by binding and inactivating the iron exporter 
Ferroportin-1 (Fp-1). Furthermore, hepcidin is an acute phase reactant induced by 
inflammation, and is downregulated by anemia, hypoxia and erythropoietin. Hepcidin is 
increased in patients with ESRD, because of chronic inflammation and of reduced urinary 
excretion due to kidney injury. Hepcidin levels reduce intestinal iron absorption and iron 
recycling from monocytes, decreasing serum iron available for the erythropoiesis, thereby 
playing a causal role in the anemia of inflammation and ESRD. 
Recent data are consistent with the hypothesis that iron mediated vascular damage involves 
hepcidin upregulation with consequent accumulation of iron in macrophages, being 
hepcidin associated with carotid vascular damage independently of other known risk 
factors in high-risk populations.  Moreover, in vitro studies suggest that hepcidin synergizes 
with excess iron, by favoring intracellular accumulation of this metal in macrophages and 
oxidative stress, and the induction of the release of pro-atherogenic cytokines, in particular 
macrophage chemoattractant protein-1 (MCP-1).  
Mutations of the HFE gene responsible for the iron overload disorder hereditary 
hemochromatosis are frequently observed in the general population and uncouple the 
regulation of intestinal iron absorption from iron stores by determining altered hepatic iron 
sensing and a relative deficit in hepcidin release. These physiological alterations result in an 
attenuation of the effects of inflammation on iron metabolism, including reduced iron 
absorption, and iron sequestration in macrophages. Here we review novel data suggesting 
that HFE mutations are associated with reduced hepcidin release in CHD patients, resulting 
in an increased sensitivity to ESAs and iron supplementation, and possibly in a reduced risk 
of death due to the decreased incidence of complications related to excessive iron and ESAs 
dosages, including cardiovascular events and infections. 
These results may have important clinical implications, as targeting the HFE/hepcidin/Fp-1 
axis by pharmacological treatment may further improve the long-term outcomes of CHD, by 
reducing the amount of iron and ESAs supplementation needed and by improving iron 
utilization for erythropoiesis. 
2. Iron metabolism 
2.1 Role of iron in the cells 
Iron, like other metal ions, is an essential nutrient, playing a crucial role in vital biochemical 
activities, as components of enzymes and other molecular complexes. Excess iron promotes 
noxious free-radical reactions (Kell 2010), so that it has to be compartmentalized and 
maintained at a fixed level to avoid any toxic effects, largely based on its ability to catalyze 
the generation of radicals, which attack and damage cellular macromolecules and promote 
cell death and tissue injury. A delicately balanced iron homeostasis is achieved by 
coordinated interaction among highly evolved and regulated uptake, storage, and secretion 
processes (Papanikolaou and Pantopoulos 2005; Andrews 2008). 
2.2 Chemical properties, biological functions and toxicity of iron 
The biological functions of iron are based on its chemical properties, in particular on the 
ability to form a variety of coordination complexes with organic ligands in a dynamic and 
flexible mode, and by its favorable redox potential to switch between the ferrous, Fe(II), and 
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ferric, Fe(III), states. Iron is associated to heme and non-heme complexes. The hemoproteins 
are hemoglobin and myoglobin, cytochromes and some enzymes, such as oxygenases, 
peroxidases, nitric oxide (NO) synthases, or guanylate cyclase. All these proteins contain 
heme as prosthetic group, which is composed by protoporphyrin IX and a ferrous ion, and 
is involved in oxygen transport to muscles and tissues (hemoglobin and myoglobin), in the 
respiratory chain (e.g., cytochromes a, b and c), in the activation of substrates by oxygen 
(e.g. cytochrome oxidase, cytochrome P450, catalase) and as a NO sensor (guanylate 
cyclase). The most prevalent forms of non-heme iron are metallo-proteins with iron-sulfur 
clusters, which are involved in the respiratory chain (e.g., in complex III), DNA synthesis 
(e.g. ribonucleotide reductase), and in the inflammatory response (e.g., cyclo-oxygenases 
and lipoxygenase). It should also be noted that non-heme iron has a central function in a 
recently discovered mechanism for oxygen sensing, via the hypoxia-inducible factor (HIF), 
that controls the transcription of a wide array of genes involved in erythropoiesis, 
angiogenesis, cell proliferation/survival, glycolysis, and iron metabolism in response to 
oxygen availability.  
The efficiency of the redox reaction between ferrous and ferric ions is a fundamental feature 
for many biochemical reactions. However, this very property turns iron into a potential 
biohazard in the cell, because under aerobic conditions, iron can readily catalyze the 
generation of noxious radicals. Iron toxicity is largely based on the Fenton reaction, where 
catalytic amounts of iron are sufficient to yield hydroxyl radicals, collectively known as 
reactive oxygen intermediates (ROIs), from superoxide and hydrogen peroxide. ROIs are 
inevitable products of aerobic respiration in mitochondria and can be also generated during 
enzymatic reactions in peroxisomes, in the endoplasmic reticulum or in the cytoplasm. ROIs 
are also produced by the membrane-bound NADPH oxidase complex, mainly expressed in 
phagocytic neutrophils and macrophages during inflammation, and involved in the 
antimicrobial defense of the organism. Free radicals are highly reactive species that promote 
the oxidation of proteins, peroxidation of membrane lipids, and modification of nucleic 
acids. An increase in the steady state levels of reactive oxygen species beyond the 
antioxidant capacity of the organism, so called oxidative stress, is observed in many 
pathological conditions, such as chronic inflammation, ischemia–reperfusion injury, or 
neurodegeneration. Excess of redox active iron aggravates oxidative stress and leads to an 
accelerated tissue degeneration. Thus, under physiological conditions extracellular iron is 
exclusively bound to TF, which maintains iron soluble and nontoxic. 
2.3 Iron distribution and absorption 
The human body contains approximately 3–5 grams of iron (45–55 mg/kg of body weight in 
adult women and men, respectively). Approximately 60–70% of body iron is employed 
within hemoglobin (Hb) in circulating red blood cells; other iron-rich organs are the liver 
and muscles. Approximately 20–30% of body iron is stored in hepatocytes and in 
macrophages, to a large extent within polymers of ferritin. The remaining is primarily 
localized in myoglobin, cytochromes, and iron-containing enzymes. A healthy individual 
absorbs daily 1–2 mg of iron from the diet, which is utilized to compensate non-specific iron 
losses by desquamation of enterocytes and epidermis and, in childbearing aged women, by 
period. Erythropoiesis requires approximately 30 mg of iron per day, mainly provided by 
the recycling of iron via macrophages, which ingest senescent red blood cells (RBCs) and 
release iron, which binds to circulating TF.  
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An average daily Western diet contains approximately 15 mg of iron, from which only 1–2 
mg is absorbed in the jejunum: in spite of such an apparently low requirement, dietary 
deficit of iron is a worldwide problem. Two thirds from absorbed iron derives from heme, 
mainly from myoglobin and hemoglobin of animal origin. The inorganic iron is not 
efficiently absorbed, but each transmembrane transport step is mediated by specific set of 
transport proteins and accessory enzymes that change the oxidation state of iron to facilitate 
the transport process. The low gastric and duodenal pH dissolves ingested inorganic iron 
and facilitates its enzymatic reduction to the ferrous form by the ferrireductase on the 
enterocyte brush border (DCYTB, duodenal cytochrome b), whose expression increases 
during iron deficiency. Ferrous iron is transported across the apical membrane by DMT1 
(divalent metal transporter-1). Inside absorptive enterocytes, heme iron is enzymatically 
released by heme oxygenase-1 (HO-1), after having been transported by heme-carrier 
protein-1 (HCP-1), and follows the fate of inorganic iron: it is either stored in ferritin or 
transported across the basolateral membrane to plasma TF. The transport across basolateral 
membrane is mediated by Fp-1, also known as IREG1 (iron regulated transporter 1), or 
SLC40A1. Fp-1 is expressed in Kupffer cells and on the basolateral membrane of enterocytes, 
macrophages, placental cells and hepatocytes, where it works as iron exporter in association 
with the plasma ferroxidase ceruloplasmin (Cp), even if enterocytes depend heavily on the 
expression of an analogous transmembrane protein called hephaestin. Ferrous iron crosses 
the plasmatic membrane through a facilitate diffusion mechanism and Cp / hephaestin 
converts it to ferric state while it is still associated to the transporter protein. Ferric iron 
bounds to plasmatic apotransferrin (the iron-free form of TF, a glycoprotein synthesized in 
liver, retina, testis and brain) to form ferric iron-TF complex, which is the major type of iron 
present in blood. A small amount of iron circulates bound to albumin or other small 
molecular weight ligands, such as citrate salts. The TF complex facilitates the transport of 
iron to cells that express transferrin receptors, including erythroid progenitors, and limits 
the ability of iron to generate toxic radicals. Transferrin saturation % (TSAT) varies 
according to diurnal cycle and local circumstances. For example, TSAT is high in portal 
circulation and low in the blood leaving bone marrow, and is strongly influenced by 
inflammation, which decreases plasma iron availability in order to prevent iron utilization 
by pathogens for their replication.  
2.4 Delivery of iron to tissues and intracellular transport 
Iron uptake occurs primarily by the endocytic pathway, which involves the interaction 
between TF and transferrin receptors (TFR). Two different TFR are known, namely TFR-1, 
which is found in all cells and shows an elevated affinity for circulating TF, and TFR-2, mainly 
expressed in the liver and in the hematopoietic cells, which bind the TF complex with a lower 
affinity. Once the TF complex binds to TFR-1 at the cell surface, it is internalized in clathrin-
coated pits: in the endosome the luminal pH is maintained at about 5.5 by a vacuolar H+-
ATPase (V-ATPase). This acidification process induces conformational changes in the TF-TFR-
1 complex, with consequent release of iron in the endosome, while different ferrireductases 
operate the transformation of ferric iron into the ferrous state. The endosomal transporter 
DMT1 allows then the passage of ferrous iron in the cytoplasm. The acidic endosomal pH 
maintains apotransferrin bound to the TFR-1 and this complex is recycled on the cellular 
surface. At the more neutral plasmatic pH, apotransferrin dissociates and it can bind to 
plasmatic iron again. Not much is known about the mechanisms of intracellular iron transport 
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to organelles, but there is strong evidence for the existence of a transit pool of iron in the 
cytosol (Petrat, de Groot et al. 2002), which presumably remains bound to low-molecular-
weight chelates, such as citrate, ATP, AMP, or pyrophosphate. It is believed that the levels of 
this elusive chelatable or “labile iron pool” (LIP) reflect the overall iron status of the cell and its 
variations activate adequate homeostatic responses for iron availability. The LIP constitutes 
also a source of iron susceptible of redox-state variations, with consequent generation of free 
radicals toxic for cells. 
2.5 Iron storage and recycling 
Not all absorbed iron is utilized in metabolic processes, but it is partly stored as reserve, 
both for use when iron levels are low, and to prevent toxic effects of free iron in the cell. 
Stored iron accounts for 20-30% of body iron in physiological conditions, and the major part 
of it is bound to ferritin. This is a ubiquitous multimer of 24 subunits with a central core that 
contains up to 4,500 atoms of iron, and that possesses an important ferroxidase activity (the 
H form, whereas the L form is the storage subunit) that facilitates the oxidation of the 
cytosolic ferrous iron to the ferric state. Iron is also stored in an insoluble form into a 
protein, named haemosiderin, likely derived from the lysosomal degradation of ferritin. 
Under iron overload conditions, ferritin levels increase dramatically, particularly in liver, 
pancreas and heart. Intestinal absorption accounts for only a fraction of TF-bound iron in the 
circulation. Recovery of iron from senescent erythrocytes also plays an important role in 
iron maintenance. At the end of their lifespan, human erythrocytes undergo surface 
alterations that mark them to be phagocytosed and digested by reticulo-endothelial 
macrophages in the spleen and liver. In the macrophages iron is predominantly recovered 
from heme by the action of HO-1.  
2.6 Regulation of intracellular iron homeostasis 
Regulated expression of proteins essential for cellular iron homeostasis, such as TFR-1 and 
ferritin, is achieved by a post-transcriptional mechanism, which is dependent on biologically 
active iron levels. The messenger RNAs of these peptides present regulatory sequences 
named IRE (iron responsive elements) in the untraslated regions (UTRs), the target of iron 
regulatory proteins (IRP-1 and IRP-2), which are rapidly degraded in iron-rich condition. 
Under iron deficiency conditions, IRPs actively bind multiple IREs localized at the 3’UTR of 
some mRNAs, such as TFR-1 mRNA, determining mRNA stabilization and increased 
translation of the protein, and simultaneously decrease the translation of ferritin mRNA by 
binding to 5’UTR IRE sequences, thereby maximizing the uptake and availability of iron in 
the cell. Conversely, when the iron levels are high, decreased IRE binding facilitates efficient 
translation of ferritin mRNA and decreases the stability of TFR-1 mRNA, leading to iron 
sequestration over uptake. 
2.7 Hepcidin and systemic iron homeostasis 
Systemic iron homeostasis is achieved by modulation of the amount of iron absorbed, since 
physiological mechanisms for the regulation of iron excretion are presently unknown. 
Intestinal iron absorption is regulated in response to iron need and availability and 
erythropoiesis activity. Stewart et al first disclosed the so-called mucosal block, detecting 
that a large oral dose of iron reduced the absorption of smaller dose of iron administered 
several hours later (Stewart, Yuile et al. 1950). These observations suggested that enterocytes 
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receive signals from other tissues or cells that are involved in either utilization (erythroid 
precursors) or storage (hepatocytes, macrophages) of iron. Signals that originate from 
storage sites to balance intestinal absorption were termed “storage regulators”, while 
“erythroid regulators” signal when the consumption demand for iron in bone marrow, 
erythroid precursors and circulating erythrocytes, exceeds the amount present in stores. On 
the other hand, “inflammatory regulators” communicate signals in response to infection or 
inflammation, resulting in accumulation of iron in macrophages. Iron homeostasis is also 
influenced by hypoxia regulatory signals. Adding to the complexity, these diverse 
regulatory signals may not be completely independent of each other and elicit quantitative 
differences in response to common molecules. The amount of body storage modulates iron 
uptake: it is well established that in iron-deficient conditions, iron absorption is significantly 
stimulated by two- to three-fold compared to basal conditions, which are restored when iron 
storage are reconstituted. The erythropoietic regulation participates when iron demand for 
Hb synthesis increases, independently of body iron stores. This mechanism can explain the 
pathological iron accumulation observed in disorders characterized by ineffective 
erythropoiesis (such as thalassemia syndromes, congenital dyserythropoietic anemias, 
sideroblastic anemias).  
A small antimicrobial peptide synthesized by the liver (and to a lesser extent by 
macrophages and adipocytes), named hepcidin (Pigeon, Ilyin et al. 2001), is now retained to 
be the principal effector of the modulation of iron availability by iron stores and 
inflammation in humans. The human hepcidin gene (HAMP; OMIM 606464), located on 
chromosome 19q13.1, encodes a precursor protein of 84 amino acids (aa). During its export 
from the cytoplasm, full-length pre-prohepcidin undergoes enzymatic cleavage, resulting in 
the export of a 64 aa prohepcidin peptide into the endoplasmic reticulum lumen (Wallace, 
Jones et al. 2006). Next, the 39 aa pro-region peptide is post-translationally removed by a 
furin-like pro-protein convertase, resulting in mature bioactive hepcidin-25. In human urine, 
hepcidin-22, a N-terminally truncated isoform of hepcidin-25 considered the urinary 
degradation product of hepcidin-25, can be detected. Structural analysis of human synthetic 
hepcidin by nuclear magnetic resonance spectroscopy revealed that this 8 cysteine-
containing peptide forms a hairpin-shaped molecule with a distorted beta-sheet, which is 
stabilized by four disulfide bridges between the two anti-parallel strands. One of the 
disulfide bridges is located in the vicinity of the hairpin loop which points to a possible 
crucial domain in the activity of the molecule (Hunter, Fulton et al. 2002). Structure-function 
in vivo and in vitro studies on synthetic hepcidin have shown that the iron regulating 
bioactivity is almost exclusively due to the 25 aa peptide, suggesting that the five N-terminal 
amino acids are essential for this activity. In vitro experiments have shown that especially 
human hepcidin-20 (the other N-terminally truncated isoform detectable in human serum) 
exerts anti-bacterial and anti-fungal activity in a concentration range 10- fold higher than 
that measured in healthy individuals. Therefore, it is not clear whether in vivo hepcidin 
levels can reach values in which it can be anti-microbial, or whether this function is of 
biologic importance or only rudimentary in its evolutionary origin from the antimicrobial 
peptides of the defensin family. Hepcidin is excreted in the urine; in a murine model, its 
effect starts within 4 hours and lasts for more than 48 hours (Rivera, Nemeth et al. 2005). 
Fractional excretion of hepcidin-25 in 3-5%, because is not freely filtered or it is reabsorbed 
by the tubules like other small peptides.  
Hepcidin mediated regulation of iron metabolism has been demonstrated to depend upon its 
ability to bind Fp-1 on cellular surface blocking its iron transport activity, and to increase Fp-1 
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endocytosis, JAK2 mediated phosphorylation, and consequently its degradation by lysosomes 
(Nemeth, Tuttle et al. 2004). In enterocytes, Fp-1 internalization on the basolateral surface 
causes the retention of absorbed iron with subsequent loss by desquamation, while the same 
process in macrophages causes the failure to release iron (Pietrangelo, 2007). The final effect is 
the reduction of plasma iron availability. Besides liver hepcidin controlled reduction of iron 
uptake and release at systemic level, there is also evidence for local production of hepcidin by 
macrophages, fat cells and cardiomyocytes, suggesting a different regulatory mechanism 
related to hepcidin to control iron balance (Theurl, Theurl et al. 2008). Indeed, mutations of 
HAMP, the hepcidin gene, cause severe early-onset HH in humans, whereas deletion of Hamp 
in animal models brings to severe iron accumulation (Lesbordes-Brion, Viatte et al. 2006). 
Conversely, hepcidin producing hepatic adenomas in patients and overexpression of hepcidin 
in animal models lead to hyposideremia and iron deficiency anemia. 
Importantly, hepcidin is upregulated by both increased iron stores and inflammation. 
Indirect hepcidin inductions by IL-6 or LPS in humans displayed the same fast response in 
urinary hepcidin excretion, thereby acting like an acute phase protein with a peak value 
after 6 hours, followed by a steady decrease. When hepcidin is administered orally, a peak 
in urinary excretion appear in less than one day, suggesting a fast clearance of this peptide 
from the circulation, with a paradoxical sustained inhibitory effect on iron uptake, shown by 
the iron parameters which remained unchanged over the following days (Nemeth, Rivera et 
al. 2004). Hepcidin secretion is reduced in response to signals that cause an increase in iron 
release from cells, such as iron deprivation, and stimulus to erythropoiesis, whereas it rises 
when iron secretion is inhibited, as for iron load or for a flogistic state. Thus, hepcidin can 
represent the common effector of the homeostatic regulation of intercellular iron fluxes in 
response to the iron stores, erythroid, and inflammatory regulators. 
It is still not clear how systemic iron demand modulates hepcidin release by the liver. A 
number of molecules have been implicated in different ways of transduction of the signal: 
the alteration of each of these molecules causes an insufficient release of hepcidin resulting 
in a deregulated iron flux from macrophages and enterocytes, which finally brings to iron 
overload in blood circulation and finally in tissues. Hepcidin release may be impaired by 
genetic factors, i.e. mutations inactivating hepcidin, HJV, HFE or TFR-2, or by non-genetic 
factors: alcohol abuse (that inhibits hepcidin transcription), viral infections such as chronic 
HCV hepatitis, and acute liver insufficiency and cirrhosis (because of the reduced hepcidin 
synthesis by hepatocytes). In addition, mutations in the Fp-1 gene, which bring to 
insensitivity to hepcidin action, are as well responsible for hereditary forms of overload. 
The small size of hepcidin, the compact and complex structure of the molecule, and the 
highly conserved sequence among species, make problematical the quantitative assessment 
of serum levels of hepcidin in humans. Furthermore, about 90% of serum hepcin-25 appears 
to be bound to circulating proteins, mostly α2-macroglobulin. Recently, laboratory assays 
for hepcidin-25 (the biologically active form of the hormone) in serum and urine has been 
developed: they include competitive ELISAs using biotinylated or radio-iodinated hepcidin 
as tracers, and several mass-spectrometry-based assays using as internal standards 
isotopically labeled hepcidin or shorter hepcidin mutants. Interestingly, hepcidin levels 
were correlated with ferritin in patients with chronic kidney disease (Tomosugi, Kawabata 
et al. 2006; Kato, Tsuji et al. 2008; Kroot, Laarakkers et al. 2010). In contrast, measurement of 
serum prohepcidin, an immature form of hepcidin measured by ELISA, was found to be 
increased in patients with ESRD (Kulaksiz, Gehrke et al. 2004), but have not been found to 
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correlate with mature biologically active hepcidin and with iron stores (Kato, Tsuji et al. 
2008; Swinkels, Girelli et al. 2008).  
3. HFE mutations and iron overload 
The transcription and secretion of hepcidin by the liver is regulated by a mechanism of body 
iron sensing and is finely regulated by a group of proteins, including the hereditary 
hemochromatosis protein called HFE, TFR-2, hemojuvelin (HJV), bone morphogenetic 
protein 6 (BMP6), matriptase-2 (TMPRSS6) and TF. Mutations in HFE, TFR-2, HJV and the 
hepcidin gene (HAMP) are responsible for hereditary hemochromatosis (HH), a common 
iron overload disorder characterized by a deficit of hepcidin release or activity (Camaschella 
2005; Pietrangelo 2007). 
HFE mutations represent the most frequent cause of HH in Caucasian adults (Feder, Gnirke 
et al. 1996). HFE structure resembles MHC class I molecules and forms a heterodimer with 
β2-microglobulin. TF and HFE seem to compete in vitro for binding to TFR-1, which is 
hypothesized to sequester HFE thereby altering iron sensing and hepcidin expression. In 
this way, increased iron-loaded TF levels would result in the release of HFE with possibility 
to interact with other proteins, in particular with TFR-2, which only binds saturated TF at 
physiological concentrations. However, the exact mechanisms underpinning HFE regulation 
of iron metabolism through SMAD (son of mother against decapentaplegic) and possibly 
ERK (extracellular signal-regulated kinases) signaling are still not clear. The most common 
HFE mutation responsible for HH is a single nucleotide substitution that causes the 
substitution of a cysteine with a tyrosine at position 282 (C282Y). The homozygous genotype 
is very frequent in Caucasians, particularly in people from Northern Europe  (frequency 
1/300-400), whereas the prevalence decreases towards Southern Europe. This substitution 
brings to HFE mysfolding, resulting in failed interaction with β2-microglobulin and cell 
surface expression. A second and most frequent mutation is a substitution at position 63 of a 
histidine with an aspartate (H63D), which likely interferes with the ability of HFE to interact 
with TFR-1. This is a very common polymorphism in the general population, as 25-30% of 
the population carries the H63D variant, but its contribution to the pathogenesis of HH and 
iron overload syndromes is negligible, with the exception of compound heterozygosity with 
the C282Y. The penetrance of HH depends on age, gender, environmental factors, and on 
the role of the so-called modifier genes (Wood, Powell et al. 2008): for example, iron 
overload and clinical phenotype are more serious in patients with beta-thalassemic trait 
(Piperno, Mariani et al. 2000; Valenti, Canavesi et al. 2010).  
Mutations of TFR-2 cause a rare recessive form of HH, clinically similar to HFE HH, which 
is consistent with the hypothesis that HFE and TFR-2 might be part of the same signaling 
pathway. Indeed, it has been hypothesized that TFR-2 binds iron-loaded TF, but not iron-
depleted TF. Thus, TFR-1 and TFR-2, by binding iron bound and not bound to TF 
respectively, may contribute to modulate iron sensing and hepcidin release by the liver. 
However, deletion of Tfr-2 and Hfe had additive effects on iron overload in mice, thus 
suggesting that the pathways through which these two genes regulate iron metabolism 
might not be entirely overlapping. In addition, TFR-2 was discovered to be associated to 
erythropoietin receptor (Epo-R) in the EpoR complex, and thus to exhibit an extra-hepatic 
function, being required for efficient erythroid differentiation and erythropoiesis 
(Forejtnikova, Vieillevoye et al. 2010). Furthermore, very recently it has been demonstrated 
that also HFE is expressed in erythroblast and plays a role in the regulation of erythroid 
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differentiation, and that HFE deficiency is associated with increased erythropoiesis partly 
due to enhanced iron absorption and delivery to the erythron due to decreased hepcidin 
levels and increased TSAT, and partly due to a direct effect of HFE on the modulation of 
iron uptake in erythroid cells (Ramos, Guy et al. 2011). These new exciting findings suggest 
that the TFR-2/HFE complex is directly involved in the regulation of erythropoiesis 
independently of hepcidin levels, and thus that genetic variations of HFE and TFR-2 may 
influence RBCs production and the development of anemia in conditions characterized by 
reduced iron availability, such as CHD. 
Many other molecules have been implicated in the regulation of hepcidin secretion. Binding of 
the iron-regulated BMP6 ligand, a bone morphogenetic protein of the TGFβ superfamily, to its 
threonine/serine kinase receptors (BMPR-I and BMPR-II) activates a signaling cascade leading 
to hepcidin transcription via phosphorylation, nuclear translocation, and binding to the 
hepcidin promoter of SMAD 1/5/8 effectors (Babitt, Huang et al. 2006). HJV, a GPI-linked 
membrane protein synthesized by the hepatocytes, is a BMP6 coreceptor, which is required for 
its regulatory functions on iron metabolism. The critical role of the BMP6/HJV/SMAD 
pathway in iron homeostasis is supported by the loss of hepcidin expression and massive 
parenchymal iron overload observed in BMP6-/- and HJV -/- mice as well as in mice with 
targeted liver deletion of SMAD4 (Andriopoulos, Corradini et al. 2009), and by the fact that 
HJV mutations represent the major cause of juvenile HH. Furthermore, iron overload and 
increased TSAT have been associated with specific upregulation of BMP6 in hepatocytes and 
in vivo. However, BMP6 mutations have not been associated with HH so far. Interestingly, it 
has been shown that BMP6 levels are increased in HFE-related HH both in mice and humans, 
suggesting that HFE might be involved in the transduction of BMP6 signaling, or that BMP6 
levels are upregulated in the attempt to compensate for the lack of HFE function, but 
supraphysiological doses of BMP6 were sufficient to normalize iron metabolism in 
experimental models. Recently, the serine protease matriptase-2 has been connected to this 
iron regulatory pathway because of its ability to cleave HJV (Muckenthaler 2008). Matriptase-2 
is a type 2 transmembrane serine protease that is predominately expressed in the liver and was 
characterized as a negative regulator of hepcidin gene expression (Ramsay, Hooper et al. 
2009). Matriptase-2–deficient mice have very high levels of hepcidin, which lead to the 
inhibition of dietary iron absorption and cause a severe iron-deficiency anemia phenotype. 
This anemic phenotype is mirrored in patients with matriptase-2 mutations, who present with 
iron-refractory, iron-deficiency anemia (IRIDA). Indeed, patients with IRIDA show 
inappropriately high hepcidin levels, which explain the lack of dietary iron absorption and the 
only partial response to parenteral iron treatment (Finberg 2009). In addition, it has been 
recently recognized by means of genome-wide association studies that very common genetic 
polymorphisms in TMPRSS6 represent, together with HFE mutations, a major source of 
variability in serum iron and hemoglobin levels in the general population (Benyamin, Ferreira 
et al. 2009; Chambers, Zhang et al. 2009; Ganesh, Zakai et al. 2009; Tanaka, Roy et al. 2009). 
Severe iron overload in HH involves several organs, mainly the liver, endocrine glands, and 
heart. However, the involvement of a specific organ varies on the entity of iron 
accumulation, which depends in part also on the specific mutation at the base of the disease. 
Usually, the more severe phenotype is observed in the juvenile forms versus adult disease 
(Pietrangelo 2007), and secondary iron overload in the presence of physiological 
upregulation of hepcidin presents with a different organ involvement (mainly 
macrophages), and clinical phenotype (e.g. anemia, accelerated atherosclerosis, altered 
immune regulation) (Pietrangelo 2004).  
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4. Anemia in ESRD  
Anemia is a common problem in patients with ESRD and increases mortality and morbidity 
in these patients, especially related to cardiovascular events. The cause of anemia in patients 
with chronic kidney disease is multifactorial (Lankhorst and Wish 2010), but it is believed 
that a deficit of erythropoietin (Epo) due to kidney injury plays a major role. Indeed, it is 
generally advised that erythropoiesis-stimulating agent (ESAs) should be given to all 
patients with ESRD with hemoglobin (Hb) levels consistently (i.e. measured twice at least 2 
weeks apart) below 11 g/dl, or with haematocrit < 33%, where all other causes of anemia 
have been excluded. However, recent evidence such as those provided by the TREAT study 
(Pfeffer, Burdmann et al. 2009) warn against excessive ESAs doses, as an increased risk of 
stroke has been reported in those patients treated with ESA with a hemoglobin target of 13 
g/dl. Thus, the recommendation of an Hb level of 10 to 12g/dl in chronic kidney disease 
(CKD) patients seems adequate. 
Epo is a glycoprotein hormone that promotes the maintenance of committed erythroid 
progenitors cells, specifically the burst-forming units (BFU-E) and colony-forming units 
(CFU-E), by binding to surface receptors and preventing them from apoptosis, and 
stimulating these erythroid progenitors to differentiate into reticulocytes and RBCs. Epo is 
mainly released by the peritubular capillary endothelial cells in the kidney. Reduced 
availability of oxygen for tissue metabolic needs (during anemia, hypoxemia or impaired 
blood flow to the kidney) stimulates Epo production through HIF, whose spontaneous 
degradation is inhibited in presence of decreased oxygen delivery and iron deficiency. 
Furthermore, it has now been clearly demonstrated that Epo administration results in 
reduced hepcidin levels and increased intestinal iron absorption in CHD patients, although 
it is still debated whether Epo directly signals through its receptor in hepatocytes to 
downregulate hepcidin transcription, or its effect is indirectly mediated by hypoxia through 
stabilization of the HIF transcription factors, or by increased erythropoiesis through the 
induction of erythroid regulators of hepcidin release of the TGFβ superfamily, possibly 
including growth and differentiation factor 15 (GDF15) and twisted and gastrulation 1 
(TWSG1) (Tanno, Bhanu et al. 2007; Kato, Tsuji et al. 2008; Pinto, Ribeiro et al. 2008; Costa, 
Swinkels et al. 2009; Morelle, Labriola et al. 2009; Srai, Chung et al. 2010). Anyway, this 
mechanism seems aimed at facilitating enhanced iron delivery to the bone marrow when is 
needed for accelerated RBCs production, and suggests that the increase in Hb levels in CHD 
patients induced by Epo may be partly mediated by normalization of hepcidin levels and of 
iron delivery. Therefore, the process of erythropoiesis needs an adequate renal secretion of 
Epo, an appropriate response of bone marrow, and sufficient supply of substrates for Hb 
synthesis, such as iron, folates, and cyanocobalamin. Epo levels are significantly higher in 
patients with advanced CKD compared to general population, but inappropriately low for 
the degree of anemia. In addition, the persistence of anemia despite Epo higher levels 
suggests a concomitant hyporesponsiveness of bone marrow in these patients. 
Furthermore, in patients with CKD, RBCs life span is shortened to 60-90 days (versus 120 
days), and there is an increase tendency of bleeding due to platelet dysfunction, both for the 
presence of uremic toxins. Other causes of anemia include chronic blood loss from 
gastroenteric system and blood trapping in dialyzers, dietary restrictions, loss of taste for 
iron-rich foods, secondary hyperparathyroidism (which is associated with bone marrow 
fibrosis), increased hemolysis and decreased erythropoiesis, nutritional deficiency, and 
accumulation of inhibitors of erythropoiesis related to uremia.  
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A major condition that contributes to the establishment of anemia in CKD is the 
inflammatory state, in which the pro-inflammatory cytokines decrease EPO production and 
induce in this way apoptosis in CFU-E. In the anemia of inflammation, high levels of acute-
phase proteins, such as C-reactive protein (CRP), ferritin and in particular of hepcidin are 
detected. Recent studies unequivocally demonstrate a high prevalence of chronic systemic 
inflammation in dialysis patients. This condition has been associated with adverse clinical 
outcome (Stenvinkel, Ketteler et al. 2005),  including accelerated atherosclerosis, 
malnutrition, and pronounced anemia. Most importantly, chronic inflammation and 
cytokines can worsen anemia by reducing iron availability for hematopoiesis, shorten 
erythrocyte life span, and directly inhibit erythrocyte progenitor proliferation. Inflammation 
and cytokines are independent predictors of Epo hyporesponsiveness (Gunnell, Yeun et al. 
1999), whereas anti-inflammatory cytokines might be associated with less severe anemia 
(Stenvinkel and Barany 2002).  
5. Iron metabolism in ESRD 
ESRD, and in particular CHD, are typically associated with alteration in iron metabolism 
parameters, that is most frequently characterized by decreased TSAT, resulting in reduced 
iron availability for erythropoiesis, and is supposed to be related to chronic inflammation 
and/or blood losses (Kalantar-Zadeh, McAllister et al. 2004). Hyperferritinemia is also 
frequently observed, and although in the most severe cases excess iron administration is 
believed to play a role, in the majority of cases it is thought to reflect the malnutrition-
inflammation-cachexia syndrome (Kalantar-Zadeh, Rodriguez et al. 2004), referring to the 
state of malnutrition, chronic inflammation and wasting frequently reported in CHD 
patients, which is associated with a greater risk of cardiovascular disease and finally with a 
worse outcome (Kalantar-Zadeh, Regidor et al. 2005). It has been shown that inflammation 
and oxidative stress induce iron retention in monocytes/macrophages, and the transcription 
of ferritin, a protein with anti-oxidant activity (Scaccabarozzi, Arosio et al. 2000; Torti and 
Torti 2002). However, recent data highlight that ferritin levels reflect also iron stores in CHD 
patients. Indeed, in these subjects ferritin correlates with TSAT, with the presence of 
common mutations of the HFE gene (Valenti, Valenti et al. 2007), and with bone marrow 
iron stores (Rocha, Barreto et al. 2008). 
In CKD patients, three types of situation related to iron-metabolism are observed: 1) 
absolute iron deficiency occurs due to decreased total body iron stores. It is associated with 
serum ferritin levels <100 ng ⁄ml and with TSAT <20%. Due to very low iron stores, serum 
hepcidin is relatively low. This situation is common in patients who undergo hemodialysis, 
due to low-grade but frequent blood losses (typically 1-3 g of iron/year). 2) Functional iron 
deficiency is associated with serum ferritin levels higher than 100 ng⁄ml but TSAT less than 
20%. Iron stores are normal or even increased, but the Epo-stimulated bone marrow needs 
more iron from TF than the iron output from tissue stores, resulting in ESA resistance 
(observed in 10-20% of cases). Increased hepcidin can aggravate functional iron deficiency 
by decreasing the release of stored and macrophage iron and intestinal iron aborption, 
through Fp-1 downregulation. There is also a third type of iron deficiency-related anemia, 
the most severe and intractable form, historically termed 3) “reticuloendothelial blockage”, 
which usually occurs in the setting of acute or chronic inflammation ⁄ infection. It can be 
considered as an extreme form of functional iron deficiency and is associated with increased 
CRP levels, TSAT <20%, and normal to very high levels of ferritin. Reticuloendothelial iron 
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stores are locked, likely by hepcidin, and there is no release of iron to transferrin. Resistance 
to Epo therapy easily develops, especially if iron administration is limited by adherence to 
the “official” opinion-based upper cutoff (see below). Thus, the pattern of anemia, 
hyposideremia, ESA resistance, and high serum ferritin is frequently observed in CHD 
patients.  
As mentioned above, increased hepcidin levels are likely involved in mediating the effect of 
inflammation on iron metabolism in CHD patients. Over-expression of hepcidin, stimulated 
by inflammatory cytokines (Nemeth, Valore et al. 2003) and by the innate immune response 
through Toll-like receptor-4 (TLR4) (Peyssonnaux, Zinkernagel et al. 2006) would result in 
sequestration of iron into macrophages, decreased intestinal iron absorption and recycling, 
and finally in the decrease of iron availability for erythropoiesis. Studies in mice moderately 
overexpressing hepcidin indicate that hepcidin can also induce blunted erythropoietic 
response to Epo (Nemeth and Ganz 2009). The molecular pathway activated by the 
inflammatory response which brings to hepcidin overexpression involves the binding of 
interleukin-6 (IL-6), the major hepatic regulator of the acute phase response to inflammatory 
stimuli, to its receptor, that eventually leads to the translocation of phosphorylated signal 
transducer and activator of transcription 3 (STAT3) to the nucleus and binding to the 
hepcidin promoter, resulting in up-regulation of hepcidin transcription. It has been further 
proposed that STAT3 activation itself, without inflammation, can regulate hepcidin levels 
(Wrighting and Andrews 2006). Other pro-inflammatory cytokines may also be involved in 
modulating iron balance in chronic diseases, such as interferon-γ (IFN- γ), interleukin-1, and 
tumor necrosis factor-α (TNF-α), but the exact mechanisms are still not clear. Furthermore, 
recent evidences proved that also macrophages, in addition to hepatocytes, express hepcidin 
at low levels upon stimulation of the STAT3 pathway by IL-6, induced by 
lipopolysaccharide (LPS), or by TLR4 mediated pathways (Peyssonnaux, Zinkernagel et al. 
2007; Theurl, Theurl et al. 2008). In addition, activation of endoplasmic reticulum stress 
response by oxidative stress due to inflammation and iron overload may also play a role 
(Vecchi, Montosi et al. 2009). However, whether hepcidin release by macrophages produces 
systemic or only localized effects at the site of inflammation or bacterial invasion remains to 
be determined. 
6. Iron therapy in the anemia of ESRD 
ESAs, the recommended therapy for ESRD related anemia, increase the need for iron, as they 
stimulate the synthesis of 2 million new red cells/second (Cavill 1999), so that bone marrow 
requests strips iron off the circulating TF faster than TF can replenish it, resulting in a relative 
deficit of iron that leads the reticulocytes to enter the systemic circulation with suboptimal 
quantities of Hb (Brugnara 2000). Evidence now prove that adequate iron availability increases 
erythropoiesis and reduces ESA requirements (Besarab, Amin et al. 2000).  
According to K-DOQI guidelines (2006), iron status should be evaluated every month 
during initial ESAs treatment, at least every 3 months during stable ESAs treatment or in 
CHD patients not treated with ESAs. In clinical practice, no single test adequately monitors 
iron stores or availability. Serum ferritin is the only available blood marker of storage iron, 
but it is more reliable in non-dialytic patients than in those who underwent hemodialysis. 
Tests reflecting the adequacy of iron for erythropoiesis include TSAT, mean corpuscular 
volume (MCV), and mean corpuscular hemoglobin (MCH) and related indices, such as 
percentage of hypochromic red blood cells (PHRC) and content of Hb in reticulocytes (CHr). 
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MCV and MCH decrease to less than normal range only after long-standing iron deficiency 
and so they do not configure as good indicators of relative iron deficit. TSAT and serum 
ferritin are undoubtedly the most available serum test, but both show acute-phase reactivity 
and are poorly decodable for assessment of iron status in such state as chronic disease, 
malnutrition and inflammation; furthermore they exhibit also diuturnal fluctuations 
(Kalantar-Zadeh, Rodriguez et al. 2004). Therefore, there is an urgent requirement for novel 
markers (Wish 2006) more specific for iron deficit, especially in CHD patients, in which 
occult infections and malnutrition play a major role in determining response to therapy and 
influencing mortality. CHr is a measure of the amount of hemoglobin in red cells 1 or 2 days 
old and is a reasonably good reflection of how much iron was available to the bone marrow 
for incorporation into new red blood cells a few days before. The CHr compared favorably 
with serum ferritin and TSAT in predicting a response to intravenous iron, but the optimal 
cutoff value is still under investigation. Mean CHr in the general population is 32±3.3 pg, 
whereas levels of 26–29 pg indicate iron deficiency, which is diagnosed by the absence of 
stainable iron stores (Mast, Blinder et al. 2002). More recent evidence refers to a cutoff of 32 
pg, and determined that a CHr cutoff of 29 pg tended to miss a number of patients who 
ultimately responded to intravenous iron. The PHRC is based on the Hb concentration in 
RBCs; it takes into account the absolute amount of Hb as well as the size of the cell, but is 
poorly reliable due to the alteration observed in case of long sample transport and storage 
times. Soluble transferrin receptor levels (sTfR) provide an esteem of the iron need of the 
proliferating erythron, reflecting both erythropoietic activity and iron deficit, based on the 
fact that erythroblasts in the bone marrow will increase the presentation of membrane TFR-1 
in the setting of iron deficiency, as inadequate iron supplies in a patient stimulated with 
ESAs. Levels of sTfR correlate with TFR-1 membrane expression and also tend to be 
elevated in the presence of increased erythroid activity (Tarng and Huang 2002). However, 
there is not a wide consensus regarding cutoff and use of sTfR for the assessment of iron 
status in CHD patients.  
In patients undergoing ESAs therapy, interpretation of iron status tests should incorporate 
consideration of the Hb level and ESAs dose, in order to provide information important to 
medical decision making, because they elucidate the status of both external iron balance (net 
loss or gain of iron) and internal iron balance (disposition of iron between stores and 
circulating red blood corpuscles). For example, decreasing ferritin levels in the presence of a 
stable or decreasing Hb level may signify external iron loss, and so iron therapy is indicated. 
Conversely, decreasing ferritin levels in the presence of increasing Hb denotes an internal 
shift in iron from stores to Hb, as would be expected in a patient responding to ESA therapy: 
if iron status remains within the target range, additional iron administration may not be 
required. Finally, an increase in ferritin levels accompanied by a decrease in TSAT suggests 
inflammation-mediated reticuloendothelial blockade and may be accompanied by a 
decrease in Hb and increase in ESA dose (2006).  
KDOQI guidelines suggest that iron supplementation should be administered during ESA 
treatment to maintain serum ferritin >200 ng/ml and TSAT >20%, or CHr >29 pg/cell in 
CHD and serum ferritin >100 ng/ml and TSAT >20% in ESRD or in patients in peritoneal 
dialysis. The upper limit of serum ferritin besides which there is no recommendation to 
routinely administer iron was set as 500 ng/ml. When ferritin level is greater than 500 
ng/ml, decisions regarding iron administration should weight ESA responsiveness, Hb and 
TSAT level, and the patient’s clinical status. Indeed, iron determination by means of 
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magnetic susceptometry showed hepatic non–heme iron concentration greater than the 
upper limit of normal in patients with ferritin > 500 ng/ml (Canavese, Bergamo et al. 2004).  
The preferred route of iron administration in CHD patients is by intravenous (IV) infusion, 
since iron absorption from the gastrointestinal tract may be impaired in uremic patients 
(Eschbach, Cook et al. 1970; Donnelly, Posen et al. 1991; Kooistra and Marx 1998), likely 
because of high hepcidin levels. In ESRD or peritoneal dialysis patients, iron can be 
administered either orally or IV. The lack of data from clinical trials does not permit to state if 
a continuous iron supplementation is better than a periodical one. Available intravenous iron 
formulations include iron dextran, sodium ferric gluconate, and iron sucrose: all these forms 
may be associated with acute adverse effects, occasionally severe, including hypotension with 
or without other symptoms and signs, possibly for immune-mediated mechanisms (mast cell–
mediated processes leading to a clinical syndrome resembling anaphylaxis), or for the release 
of small amounts of bioactive, partially unbound iron into the circulation, resulting in 
oxidative stress and hypotension (labile or free iron reactions). The pathogenesis may differ 
depending on the type of IV iron: anaphylactoid reactions appear to occur more frequently 
with iron dextran and high molecular weight forms (Novey, Pahl et al. 1994), whereas labile or 
free iron reactions occur more frequently with nondextran forms of iron (Agarwal, Vasavada 
et al. 2004; Agarwal 2006). Thus, resuscitative medication and personnel trained to evaluate 
and resuscitate anaphylaxis should be available whenever a dose of iron dextran is 
administered (2006). As a result, FDA has issued a ‘‘black box” warning, recommending that 
patients undergo a 25 mg test dose the first time the drug is given. If a patient does not have an 
adverse reaction to this dose, he/she is less likely to have an anaphylactic reaction to the 
therapeutic dose of iron dextran, but fatal anaphylactic reactions still occur with an uneventful 
test dose (Lankhorst and Wish 2010). 
7. Iron toxicity in ESRD 
Before the ESAs era, CHD patients often developed severe iron overload, frequently with 
ferritin levels >1000 ng/ml, due to polytransfusion. Nowadays, patients with anemia of CKD 
are supplemented with IV iron to correct the relative deficiency linked to the ESAs therapy. 
However, large doses of iron may exceed storage capacity leading to the accumulation of 
unbound iron in plasma, which as seen before, via the Fenton reaction, can produce reactive 
oxygen species (Michelis, Gery et al. 2003). In addition, different formulation of IV iron are 
associated with various degree of oxidative stress: iron sucrose, for example, determines a 60% 
greater elevation in tumor necrosis factor alpha (TNFα), a proinflammatory cytokine, 
compared with either iron dextran or ferric gluconate (Zager 2005).  
Moreover, iron has been implicated in the pathogenesis of the accelerated atherosclerosis in 
CHD (Griendling and FitzGerald 2003), in addition to traditional and population specific 
risk factors such as anemia, hyperhomocysteinemia, hyperphosphatemia and inflammation. 
It has been suggested that iron overload may increase cardiovascular risk in the general 
population, by affecting LDL oxidation and endothelial dysfunction (Roest, van der Schouw 
et al. 1999; Zacharski, Chow et al. 2000; Wolff, Volzke et al. 2004) and administration of 
intravenous iron has been associated with increased oxidative stress (Michelis, Gery et al. 
2003). In CHD patients, carotid intima media thickness (an early index of atherosclerosis and 
a strong predictor of cardiovascular events) and carotid plaques were positively correlated 
with serum ferritin and oxidative stress and reduced plasma anti-oxidant activity (Drueke, 
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Witko-Sarsat et al. 2002; Valenti, Valenti et al. 2007), and intima-media thickness was also 
associated with the dose of IV iron administered (Reis, Guz et al. 2005). Furthermore, 
hepcidin and TNFα levels have also been correlated with vascular stiffness, another reliable 
predictor of cardiovascular events in CHD (Kuragano, Itoh et al. 2011). The mechanism may 
involve iron trapping into endothelial cells, plaque macrophages, and vascular smooth 
muscle cells, with activation of the atherogenic process and progression of the plaque lesion. 
Indeed, a significantly higher iron content has been detected in atherosclerotic plaques than 
in healthy vascular tissue (Stadler, Lindner et al. 2004). Hyperferritinemia (beyond 800 
ng/ml) was found to be associated with imminent death risk, and cardiovascular death in 
hemodialytic patients (Kalantar-Zadeh, Don et al. 2001; Kalantar-Zadeh, Regidor et al. 2005), 
even if this association might not reflect only iron toxicity, since hyperferritinemia 
associated morbidity is partially explained by non-iron-related factors, such as 
proinflammatory cytokine release and the malnutrition inflammation cachexia syndrome. 
However, even after adjustment for these confounding variables, high ferritin levels and the 
intravenous dose of iron were still associated with increased total and cardiovascular 
mortality (Feldman, Santanna et al. 2002; Kalantar-Zadeh, Regidor et al. 2005). In particular, 
recent data from our group confirm that in CHD patients, hyperferritinemia reflects a 
relative increase in iron availability and a decrease in iron-specific anti-oxidant activity, is 
favored by HFE mutations, and represents a risk factor for advanced cardiovascular 
damage, as evaluated by the presence of plaques, both at carotid and femoral arteries 
(Valenti, Valenti et al. 2007). 
Recent evidence (Neven, De Schutter et al. 2011) confirm a strict relation between iron and 
vascular damage in CHD patients, suggesting that the mechanism underpinning this 
association may involve the predisposition to arterial wall calcification. Indeed, increased 
oxidative stress, associated with iron overload, promotes in vitro a shift in vascular smooth 
muscle cells from a contractile to an osteogenic phenotype (Byon, Javed et al. 2008), as 
indicated by an increased expression of Runx2, a key transcription factor for osteogenic 
differentiation. Meanwhile, ROIs seem to inhibit osteoblastic differentiation and 
mineralization in bones (the so called calcification paradox of bone-vascular axis) (Parhami, 
Morrow et al. 1997; Persy and D'Haese 2009); both these processes may depend on an iron-
induced upregulation of ferritin and an increase in ferroxidase activity. Furthermore, iron 
overload itself has been associated with osteoporosis and increased bone reabsorption 
(Valenti, Varenna et al. 2009). Reactive species stimulates also apoptosis in vascular smooth 
cells, providing in this way a nidus for the deposition of calcium-phosphate crystals 
(Reynolds, Joannides et al. 2004; Shroff, McNair et al. 2008), which could be directly 
promoted by iron salts (Neven, De Schutter et al. 2011), and promoting thus vascular 
calcifications and an increased cardiovascular risk for ESRD patients. 
Moreover, iron overload has been associated with an increased incidence and severity of 
infections, which, besides the known growth-promoting effect of iron on microbial pathogens, 
have been also related to inhibition of phagocytosis (Cieri 1999), and to inhibition of the anti-
microbial molecule lactoferrin (Ellison and Giehl 1991). Both iron sucrose and ferric gluconate 
have been shown to result in impaired trans-endothelial polymorphonuclear leukocytes 
migration in vitro (Sengoelge, Kletzmayr et al. 2003). Iron is an essential nutrient for bacterial 
microorganisms, and several bacterial species (including E. coli, Klebsiella spp., Pseudomonas 
spp., and Salmonella spp) can compete with TF for unbound iron in the blood by means of 
bacterial iron chelators, named siderophores (Cieri 1999; Brewster and Perazella 2004). Other 
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bacterial species, such as Staphylococcus aureus and Haemophilus influenzae express transferrin 
receptors, which allow these bacteria to use iron for growth. Infection risk in CKD patients 
depends not only on iron, but also on the severity of anemia (Hershko, Peto et al. 1988), 
transfusions, secondary splenic dysfunction, and the presence of catheters for hemodialytic or 
endovenous therapies. Although human data are not conclusive, it is still recommended that, 
as a precaution, IV iron is stopped in patients with ongoing bacteraemia, as in vitro and in vivo 
studies demonstrated that administering IV iron during active infection may contribute to 
bacterial growth (Zager 2005; Zager, Johnson et al. 2005). Nevertheless, correction of anemia is 
effective in reducing oxidative stress and, consequently, cardiovascular risk, decreasing 
morbidity and mortality and also producing regression of left ventricular hypertrophy in 
patients with CKD (Ayus, Go et al. 2005), so that a carefully balanced management of iron 
supplementation is needed in ESRD patients. 
8. Role of hepcidin in anemia of ESRD 
Increased hepcidin levels have been hypothesized to contribute explaining many typical 
alterations of iron metabolism in CHD patients, and to the pathogenesis of anemia in ESRD 
(Kulaksiz, Gehrke et al. 2004; Tomosugi, Kawabata et al. 2006; Malyszko and Mysliwiec 
2007; Kato, Tsuji et al. 2008; Kemna, Tjalsma et al. 2008), an almost universal finding 
associated with increased mortality (Paganini 1989; Locatelli, Pisoni et al. 2004). As 
mentioned above, although treatment with ESAs and IV iron formulations (Locatelli, Aljama 
et al. 2004) are generally prescribed, functional iron deficiency is a common finding, 
determining the need for high doses of ESAs and iron, both associated with adverse events. 
Indeed, high ESAs doses have been associated with mortality due to cardiovascular events 
related to hypertension and hypercoagulability (Miyashita, Tojo et al. 2004; Phrommintikul, 
Haas et al. 2007; Strippoli, Tognoni et al. 2007), whereas excess iron promotes vascular 
damage by inducing oxidative stress, and heightens the risk of infections (Seifert, von 
Herrath et al. 1987; Jean, Charra et al. 2002; Teehan, Bahdouch et al. 2004; Kalantar-Zadeh, 
Regidor et al. 2005; Valenti, Valenti et al. 2007).  
The mechanism proposed to explain refractoriness to IV iron was previously related to the 
inhibition of erythropoiesis and iron recycling from macrophages by inflammation (Stenvinkel 
2003). Increased hepcidin may be involved in mediating the effect of inflammation by 
reducing intestinal iron absorption and iron recycling from monocytes (Pietrangelo 2007), 
decreasing serum iron available for the erythropoiesis (Camaschella 2005) and the therapeutic 
effect of ESAs and intravenous iron (Malyszko and Mysliwiec 2007). Furthermore, in CKD the 
renal clearance of hepcidin diminishes gradually with the progression of kidney disease, with 
some studies reporting an inverse correlation between glomerular filtration rate and serum 
hepcidin. Thus, the severity of kidney injury directly influences hepcidin levels contributing to 
anemia via this mechanism. Importantly, preliminary data indicate that hemodialysis reduce 
serum hepcidin levels (Zaritsky, Young et al. 2010), contributing to anemia management, but 
whether specific dialytic techniques differentially affect hepcidin clearance is still unknown. 
Finally, chronic iron supplementation is a strong inducer of hepcidin also in CHD patients, 
thereby paradoxically hampering the optimal utilization of large doses of administered iron. 
Indeed, overall evidence indicate that serum ferritin and C reactive protein levels, reflecting 
iron stores and inflammation, are the major determinants of hepcidin levels in CHD and ESRD 
(Tomosugi, Kawabata et al. 2006; Kato, Tsuji et al. 2008; Valenti, Girelli et al. 2009). Supporting 
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a causal role of increased hepcidin in the pathogenesis of anemia, hepcidin-25 levels have been 
correlated with hyposideremia and the severity of anemia in patients with stable Hb values 
(Valenti, Valenti et al. 2008).  Moreover, we recently reported that frequent mutations in the 
HFE gene, which decrease hepcidin response to iron stores (Piperno, Girelli et al. 2007; Vujic 
Spasic, Kiss et al. 2008), are associated with increased sensitivity to ESAs and iron in CHD 
patients, and may be associated with a better clinical outcome (Valenti, Valenti et al. 2008). 
However, in a preliminary report hepcidin-25 was not significantly associated with Epo 
responsiveness (Kato, Tsuji et al. 2008), and in another recent study an association between 
greater iron doses, increased darbepoietin resistance index, and low hepcidin levels, possibly 
downregulated by ESAs and anemia, was detected (Bratescu, Barsan et al. 2010), thus 
suggesting that other mechanisms besides increased hepcidin are involved in the pathogenesis 
of anemia in CHD. All in all, these recent studies suggest that hepcidin is involved in the 
pathogenesis of anemia in CKD and chronic diseases, but is not the only player involved. 
9. Influence of HFE mutations on iron metabolism regulation, hepcidin levels, 
and erythropoiesis in CHD patients 
9.1 HFE mutations, iron metabolism, and erythropoiesis 
As in the general population, in CKD patients iron metabolism homeostasis and iron stores 
depend from the interaction between genetic and environmental factors, including iron 
administration. Among the candidate genetic factors that have been considered, the effect of 
HFE genotype on iron overload in CHD patients was analyzed in a few small studies with 
inconsistent results. In a recent study from our group, the presence of the C282Y or H63D HFE 
mutations was associated with increased iron stores in Italian patients (Valenti, Valenti et al. 
2007), whereas previously other Authors found only a nonsignificant, modest effect of the 
more common H63D mutation on serum ferritin (Pericole, Alves et al. 2005), and lower iron 
requirement in the few subjects carrying the C282Y HFE mutation (Canavese, Bergamo et al. 
2002). Since the C282Y and H63D HFE mutations uncouple the regulation of intestinal iron 
absorption from iron stores, by modifying hepatic iron sensing and defective release of 
hepcidin (Gehrke, Herrmann et al. 2005), we hypothesized that these genetic variants may also 
influence iron mobilization from macrophages after therapeutic iron infusion and ESAs 
treatment by influencing hepcidin release. Consistently with previous data (Canavese, 
Bergamo et al. 2002), we showed that the two common C282Y and H63D mutations, present in 
about one third of subjects, were associated with a lower requirement of ESAs and a trend to a 
lower requirement of iron (Valenti, Valenti et al. 2008). The lower baseline ESAs and iron 
requirement in mutation carriers indicate that the alterations in iron metabolism include not 
only increased iron stores, but possibly also iron handling by macrophages after infusion, and 
iron availability to the erythron. HFE mutations attenuate the effects of inflammation on iron 
metabolism, including reduced iron absorption, iron sequestration in macrophages, and 
erythroblast resistance to Epo, and protect against iron-related damage by favoring the 
delivery of intravenously administered iron to the erythron. Importantly, in this study iron 
stores were not lower, and the requirement of iron and ESAs were not higher in HFE 
H63D/wt compared to C282Y/wt and H63D/H63D patients. In subjects without ESRD, 
chronic inflammation, and liver disease, simple heterozygosity for the H63D or the C282Y HFE 
mutations was not found to be associated with either iron overload (Adams, Reboussin et al. 
2005) or reduced hepcidin release (Bozzini, Campostrini et al. 2008), and previous data 
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obtained in a very limited number of CHD patients did not support an influence of increased 
hepcidin on Epo requirement (Kato, Tsuji et al. 2008). It could therefore be speculated that 
chronic inflammation and blood losses of CHD may provide enough environmental pressure 
to magnify subtle alterations in cellular iron handling in carriers of the milder and more 
common H63D mutation, which thus reach clinical significance, unlike to what we observed in 
general population (Adams, Reboussin et al. 2005), and that the effect of HFE mutations might 
not be limited to modulation of serum hepcidin levels. Thus, in the setting of HDT 
paradoxically HFE mutations protect against iron related damage by favoring the delivery of 
intravenously administered iron to the erythron. 
9.2 HFE mutations and survival 
Furthermore, although due to the limited number of patients considered and the inclusion 
of prevalent patients in the analysis results should interpreted with caution, our data 
strikingly highlighted that the presence of HFE mutations was associated with a reduced 
hazard ratio of death. An updated mortality curve for cardiovascular disease and infection 
in 127 Italian CHD patients subdivided according to the presence or not of the C282Y and 
H63D HFE mutations is shown in figure 1. It is worthy of note that, in patients negative for 
HFE mutations, we observed a higher mortality due to sepsis, previously associated with a 
higher iron dosage (Jean, Charra et al. 2002; Teehan, Bahdouch et al. 2004), and due to 
cardiovascular disease, possibly linked to hypertension and thromboembolic events related 
to ESAs (Miyashita, Tojo et al. 2004; Phrommintikul, Haas et al. 2007) and oxidative stress 
related to iron (Valenti, Valenti et al. 2007).  
 
 
Fig. 1. Effect of HFE mutations on mortality for cardiovascular causes or infections in 127 
Italian CHD patients. 
9.3 HFE mutations and hepcidin release 
In the hypothesis that altered regulation of hepcidin release by iron stores might explain the 
apparent protective role of the HFE mutations on cardiovascular complication and on the 
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response to ESAs therapy (Valenti, Girelli et al. 2009), we recently investigated in the largest 
series of CHD patients analyzed for serum hepcidin levels to date, and the first one in which 
a quantitative assay was used, whether the effect of common HFE gene mutations on 
hepcidin-25 could be involved in the pathophysiology of the alterations of iron metabolism 
and anemia. Our data clearly confirmed and extended previous reports based on a 
semiquantitative assay in smaller series, suggesting substantial hepcidin-25 upregulation in 
CHD patients compared to controls (Tomosugi, Kawabata et al. 2006; Kemna, Tjalsma et al. 
2008), and preserved regulation of hepcidin-25 by iron stores and inflammation in this 
setting (Tomosugi, Kawabata et al. 2006; Kato, Tsuji et al. 2008). They also provided 
evidence of a modulating effect of HFE mutations, both the C282Y and the H63D mutations, 
on hepcidin-25 regulation by iron stores. First, we showed that hepcidin-25 levels are higher 
in patients receiving CHD than in healthy controls. Notably, while the groups studied were 
matched for gender, that is a major determinant of serum hepcidin levels (Ganz, Olbina et 
al. 2008; Swinkels, Girelli et al. 2008), CHD patients were significantly older than controls. 
However, this is unlikely to represent a substantial bias, since previous studies did not show 
a consistent increase in hepcidin levels with age in the general population (Ganz, Olbina et 
al. 2008). These data suggest that ESRD itself plays a role in hepcidin-25 accumulation in this 
setting. Also, we showed preserved regulation of hepcidin-25 levels by iron stores, as 
demonstrated by the very strong correlation with serum ferritin, and modulation by 
inflammation, as detected by CRP levels. Again, these data match closely those previously 
obtained showing a correlation of hepcidin-25 with ferritin and IL-6, but not CRP, in CHD, 
and, anecdotally, an increase in hepcidin-25 after IV iron administration (Tomosugi, 
Kawabata et al. 2006; Kato, Tsuji et al. 2008). Moreover, for the first time we were able to 
demonstrate a negative correlation between hepcidin-25 and serum iron, and we found that 
in a subgroup of patients with stable disease, selected to avoid the confounding effect of the 
frequent presence of acute inflammation, blood losses, cancer, and recent variation in the 
dosage of therapy, hepcidin-25 negatively correlated with Hb levels, and with a trend 
towards a negative correlation with lower serum iron. Since anemia and hyposideremia 
should rather decrease hepcidin levels, these findings suggest that hepcidin-25 plays a 
causal role in determining anemia by reducing iron availability to the erythron. To our 
knowledge, this is the first evidence supporting the theory that hepcidin is involved the 
pathogenesis of the anemia of CHD. These results imply that in CHD excessive iron 
administration may paradoxically hamper iron utilization for erythropoiesis by trapping 
iron in phagocytes, because of excessive hepcidin-25 induction favored by chronic 
inflammation, and that the effect of inflammation on altered iron metabolism and 
erythropoiesis may be mediated by increased hepcidin levels. They also suggest, together 
with the survival data in this same cohort shown above, that pharmacological 
downregulation of hepcidin (Babitt, Huang et al. 2007) may be beneficial in CHD. The subtle 
effect of HFE mutations on hepcidin release is likely magnified in CHD patients by the 
environmental pressure determined by chronic inflammation, and exposure to high 
amounts of iron and ESAs, thereby reaching clinical significance. 
However, the protective effect of HFE mutations might not be limited to enhanced 
erythropoiesis related to relatively lower hepcidin levels. Indeed, as reported above, HFE 
protein seems to be directly implicated in the maturation of erythroblasts, and lack of 
functional HFE in erythroid precursors favors erythropoiesis and is associated with 
increased Hb levels independently of the effect on hepcidin levels (Ramos, Guy et al. 2011). 
In addition, another recently discovered role of HFE is the regulation of iron uptake and 
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inflammatory response in monocytes and macrophages. It has indeed been demonstrated 
that in the presence of mutated HFE human macrophages have a deficient response to 
inflammatory stimuli, which is likely related to an impaired ability to retain iron, NFκB 
activation, and cytokine release, and that hepcidin upregulation by inflammation is also 
impaired in the absence of functional HFE (Roy, Custodio et al. 2004; Wang, Johnson et al. 
2008; Valenti, Dongiovanni et al. 2011; Wallace, McDonald et al. 2011).  
9.4 Iron, HFE mutations and atherogenesis 
Contrasting evidence suggest that iron deposition in the arterial wall may favor 
atherogenesis (Sullivan 2007). As a consequence of reduced hepcidin levels and lower 
inflammation, HFE mutations may play a protective role also in vascular damage related to 
atherosclerotic process, the major cause of mortality in CHD patients. In a large series of 
patients with metabolic syndrome alterations (Valenti, Swinkels et al. 2010), we observed 
that serum ferritin, reflecting iron stores, was an independent predictor of vascular damage, 
but only in patients negative for HFE genotypes predisposing to iron accumulation due to a 
relative decrease in the release of hepcidin. These data suggest that ferritin may represents a 
new marker of vascular damage, and support the controversial hypothesis that increased 
hepcidin favors atherosclerosis by inducing iron accumulation in arterial wall macrophages 
(Sullivan 2007). We found that ferritin levels were independently associated with common 
carotid arteries intima-media thickness, reflecting early vascular damage and a strong 
predictor of cardiovascular events, and very strongly associated with the presence of carotid 
plaques, possibly because of an additional effect of iron on the promotion of the 
complication of atherosclerosis by favoring endothelial damage and thrombosis (Day, 
Duquaine et al. 2003). The association between ferritin and vascular damage may thus be 
explained by the atherogenic effect of increased iron stores (Lee, Shiao et al. 1999; Duffy, 
Biegelsen et al. 2001; Wolff, Volzke et al. 2004; Lapenna, Pierdomenico et al. 2007), possibly  
mediated by increased hepcidin levels that determine iron trapping into monocytes, thus 
promoting transformation into foam cells in the presence of an atherogenic environment 
(Yuan, Li et al. 2004; Kraml, Klein et al. 2005; Sullivan 2007). Following this hypothesis, HFE 
mutations would be protective by decreasing hepcidin release and favoring iron egress from 
macrophages. Our data are consistent with the hypothesis that iron mediated vascular 
damage involves hepcidin upregulation, a mechanism that could be implied also in the 
enhanced atherosclerotic process in CHD patients, in which as explained before, hepcidin 
levels are more elevated than in general population.  
To further investigate the mechanisms involved in iron-mediated atherogenesis and explain 
the protective effect of HFE mutations, we next investigated the effect of iron treatment on the 
activation and secretion of atherogenic molecules in differentiating monocytes of subjects with 
different HFE genotypes. Treatment with iron salts, determining increased intracellular iron, 
enhanced the release of the macrophage chemoattractant protein-1 (MCP-1) and of IL-6 
independently of oxidative stress in differentiating monocytes derived from patients with 
metabolic syndrome (Valenti, Dongiovanni et al. 2010). Furthermore, the iron-dependent 
induction of the MCP-1 and IL-6 was associated with the severity of vascular damage in these 
patients, suggesting that macrophage activation by iron may be involved in the pathogenesis 
of atherosclerosis progression in these patients also in vivo. IL-6 is a pro-inflammatory cytokine 
involved in the acute phase response, whose serum levels correlate with cardiovascular risk 
and have been linked to the inflammatory status within atherosclerotic plaques (Luc, Bard et 
al. 2003). MCP-1 (also known as CCL2), is a chemokine involved in macrophage recruitment at 
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inflammation sites released by macrophages, but also by smooth muscle cells and endothelial 
cells. MCP-1 plays a crucial role in both the initiation and progression of atherosclerosis, and 
its serum levels reflect the atherosclerotic plaque burden. Higher MCP-1 has also been 
reported to represent a negative prognostic factor in acute coronary syndromes (Nelken, 
Coughlin et al. 1991; Gu, Okada et al. 1998; Amasyali, Kose et al. 2009). A dose-dependent 
induction of MCP-1 transcription and release in the supernatant induced by iron treatment 
was confirmed in monocytes of healthy subjects with normal iron parameters, suggesting that 
this represents a physiological response to increase intracellular iron availability. These data 
are in line with previous experimental evidence, suggesting that iron may induce MCP-1 
release by oxidative stress in macrophages. Indeed, intravenous iron treatment induces MCP-1 
release by monocytes in mice and patients with ESRD (Zager 2005; Agarwal 2006), whereas the 
iron chelator deferoxamine have recently been shown to decrease NFκB and consequently 
MCP-1 release. Importantly, we also showed that treatment with hepcidin mimicked the effect 
of iron salts on MCP-1 release. This evidence led to another confirmation of the fundamental 
pathogenic role of hepcidin on atherogenic process. In addition, we obtained evidence that, as 
it occurs in the presence of homozygosity for the C282Y HFE mutation (Garuti, Tian et al. 
2010), monocytes of patients with HFE genotypes predisposing to mild iron overload show 
reduced ability to accumulate intracellular iron. Iron induced upregulation of MCP-1 and IL-6 
was prevented in monocytes of patients carrying these HFE genotypes “at risk”, thus 
suggesting that the hampered upregulation of pro-inflammatory mediators may contribute to 
explain the lack of association between iron overload and accelerated atherosclerosis in HH 
patients, and the contradictory data on the effect of HFE mutations on vascular damage 
(Sullivan 2007; Engberink, Povel et al. 2010). Consistently, despite the fact that iron overload 
has been associated with increased serum MCP-1 levels, patients homozygous for the C282Y 
HFE mutation had lower levels than those whose iron overload was explained by other 
genetic/acquired factors and healthy controls (Lawless, White et al. 2007). We also measured 
serum MCP-1 levels in a series of patients at high risk for vascular disease because of 
metabolic syndrome, who typically display a high prevalence of altered iron metabolism 
(Valenti, Swinkels et al. 2010). In line with a possible induction of MCP-1 release by increased 
iron in monocytes/macrophages, serum MCP-1 levels, whose primary source is represented 
by activated macrophages, were significantly correlated with hepcidin-25, and MCP-1 levels 
were an independent predictor of the presence of carotid plaques, indicating an advanced 
atherosclerotic process. Thus, the emerging details of the physiology of hepcidin suggest a 
resolution of the apparent paradox of an important role of iron in atherogenesis in the absence 
of increased plaque burden in HH. Hepcidin, induced by iron and inflammation, acts to block 
iron recycling from macrophages by binding and causing internalization and degradation of 
ferroportin, the sole cellular iron exporter. Low hepcidin levels are observed in iron deficiency 
anemia and HH, both characterized by reduced macrophage iron stores. The failure of 
vascular wall macrophages to retain iron in HH may therefore prevent the progression of 
atherosclerotic plaques. HFE mutations could assume a protective role in the pathogenesis of 
atherosclerotic plaques and cardiovascular disease. These data support the hypothesis that 
MCP-1 release by intralesional monocytes/macrophages, which can be iron loaded because of 
intraplaque hemorrhage, systemic iron overload, and local inflammation is involved in the 
pathogenesis of iron-induced atherosclerosis.  
9.5 Impact of HFE mutations in CKD: a model 
In healthy controls wild-type for HFE (i.e. not carrying mutations) (Figure 2A), iron 
absorption depends on the activity of Fp-1, regulated by hepcidin. Iron is necessary for the 
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production of Hb in erythroblasts, which are stimulated by Epo, secreted by the kidneys to 
stimulate the production of mature RBCs in response to anemia or a relative deficit of 
oxygen delivery to the cells. Uptake of iron-TF occurs by means of TFR-1. Iron recycled from 
senescent RBCs by macrophages exits these cells via Fp-1. Hepcidin, secreted by the liver 
and excreted by the kidneys, promotes the degradation of Fp-1, thus inhibiting enteric 
absorption and the release of iron from macrophages. HFE is bound to TFR- 1 and is 
involved in the transmission of signaling that finally brings to the finely tuned secretion of 
hepcidin, in agreement with iron status. This regulatory pattern involves also BMP6, HJV 
and many other molecules, and converges on the activation of SMADs. In patients with 
ESRD wild type for HFE mutations (Figure 2B), the presence of proinflammatory cytokines, 
through IL-6 release and the activation of STAT3, and the impairment of renal excretion 
enhance the concentration of hepcidin, and consequently cause the impairment of iron 
absorption from the enteric lumen and of the excretion from macrophages: iron stores are 
not depleted so ferritin levels are high, but few iron circulates into the blood, so that TSAT is 
low. The erythroblasts have not sufficient iron to support Hb production and, along with 
Epo deficiency due to renal dysfunction, this provokes a significant reduction in RBCs 
production, which consequently leads to anemia. Furthermore, iron overload in 
macrophages predisposes to enhanced oxidative stress and accelerated atherosclerosis, and 
increases the susceptibility to infections. Conversely, patients with ESRD and mutations of 
HFE gene (C282Y and/or H63D) (Figure 2C) display a milder degree of anemia, since these 
mutations uncouple the hepatic iron sensing and lead to a relative deficit in hepcidin 
secretion, to a reduced cytokines release and to an improvement of erythropoiesis. In this 
way, more iron is absorbed from the gut, TSAT is only moderately diminished, and less iron 
remains trapped into macrophages. Finally, less severe oxidative stress is observed, 
contributing to the possible reduction in mortality and better response to ESAs therapy. 
 
 
Fp-1: ferroportin 1, EPO: erythropoietin, Epo-R: erythropoietin receptor, IL6: interleukine 6, HJV: 
hemojuvelin, BMP6: bone morphogenetic protein 6, BMP-R: bone morphogenetic protein receptor, TFR: 
transferrin receptor, HFE: hereditary hemochromatosis protein, STAT3: Signal transducer and activator 
of transcription 3, SMADs: small mother against decapentaplegic, Hb: hemoglobin, RBCs: red blood 
cells, TSAT: transferrin saturation. 
Fig. 2. (A) A model of the impact of HFE mutations in chronic renal disease (see text).  
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Fp-1: ferroportin 1, EPO: erythropoietin, Epo-R: erythropoietin receptor, IL6: interleukine 6, HJV: 
hemojuvelin, BMP6: bone morphogenetic protein 6, BMP-R: bone morphogenetic protein receptor, TFR: 
transferrin receptor, HFE: hereditary hemochromatosis protein, STAT3: Signal transducer and activator 
of transcription 3, SMADs: small mother against decapentaplegic, Hb: hemoglobin, RBCs: red blood 
cells, TSAT: transferrin saturation. 
Fig. 2. (B), (C) A model of the impact of HFE mutations in chronic renal disease (see text). 
10. Hepcidin targeting therapies for the management of the anemia of ESRD 
and CHD 
Overall evidence thus suggest that HFE mutations are associated with reduced serum 
hepcidin levels in CHD patients, and result in a reduced need of ESAs and iron 
supplementation, thus conferring a possible benefit on survival, in particular by reducing 
cardiovascular and infectious complications (Valenti, Valenti et al. 2008; Valenti, Girelli et al. 
2009). These results may have important clinical implications, as they suggest that targeting 
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the HFE/hepcidin/ferroportin-1 axis by pharmacological treatment (Babitt, Huang et al. 
2007), which is now under extensive investigation for the treatment of anemia of chronic 
disease (Nemeth 2010), may further improve the long-term outcomes of CHD, by reducing 
the amount of iron and ESAs supplementation needed and by improving iron utilization for 
erythropoiesis (Babitt and Lin 2010). 
Several drugs are under development for the modulation of the release and activity of 
hepcidin. The approaches under study include neutralizing anti-hepcidin antibodies (Sasu, 
Cooke et al. 2010), inhibitors of BMP type I receptors such as dorsomorphin (Yu, Hong et al. 
2008), soluble HJV, which acts as decoy receptor inhibiting BMP signaling (Babitt, Huang et 
al. 2007), and ESAs themselves, which can directly or indirectly inhibit hepcidin release 
(Pinto, Ribeiro et al. 2008). 
In a mouse model of anemia of chronic disease (ACD) caused by injections of heat-killed 
Brucella Abortus (Sasu, Cooke et al. 2010), neutralizing antibodies (Abs) directed against 
hepcidin were able to restore the reticulocyte response and normal Hb levels in combination 
with ESAs, whereas ESAs alone, and importantly ESAs plus IV iron, were ineffective. 
Furthermore, over-expression of hepcidin in mice was sufficient to hamper the 
erythropoietic response to ESAs. It is therefore conceivable that administration of anti-
hepcidin antibodies could restore ESAs susceptibility in the roughly 10% of CHD patients, 
who display ESAs resistance due to chronic inflammation and high hepcidin levels. These 
preliminary preclinical data suggest that it is unlikely that therapies that antagonize 
hepcidin would result in the control of anemia when administered alone, but they could 
restore susceptibility in patients with ESAs resistance or reduce the dose of ESAs and iron 
required to achieve anemia control, thereby minimizing side effects. 
A different approach to control hepcidin activity is represented by the modulation of 
hepcidin expression by targeting bone morphogenetic proteins (BMPs) activity. Soluble 
forms of HJV (sHJV), deriving from cleavage by furin or TMPRSS6, have been detected both 
in cell cultures and in human sera. Administration of sHJV (HJV.Fc) has been demonstrated 
to inhibit BMP signaling and hepcidin expression, likely by binding to BMP6 and 
preventing the interaction with BMP receptors (Andriopoulos, Corradini et al. 2009), and 
could be possibly exploited as a treatment for anemia of inflammation (Babitt, Huang et al. 
2007). It was also shown that anti-BMP6 Abs were similarly effective (Andriopoulos, 
Corradini et al. 2009). Notably, sHJV has been demonstrated to be downregulated by iron 
stores and induced by hypoxia, thus possibly being involved in hepcidin regulation by these 
stimuli. However, the physiological relevance of sHJV forms is still unknown; it has been 
hypothesized that it is released by the skeletal and cardiac muscle, where HJV is expressed, 
thus acting in response to iron deficiency and hypoxia to increase oxygen supply by 
hepcidin downregulation and increased iron availability for the synthesis of Hb, myoglobin, 
and mitochondrial cytochromes (Babitt and Lin 2010). 
A recent and promising development was provided by the recognition of the hepcidin 
suppressive activity of heparin. Heparan sulfate proteoglycans (HSPGs) are expressed on 
the surface of various cell types and in the extracellular matrix, and modulate BMP 
osteogenic activity by binding BMPs, BMP antagonist, and BMP receptors. Heparin, a 
proteoglycan analog to HSPGs, has been reported to strongly down-modulate hepcidin 
release in vitro in hepatocytes and in vivo in mice, resulting in increased serum iron and 
decreased splenic iron levels (Poli, Girelli et al. 2011). The effect was long lasting and higher 
for unfractioned than for low-molecular-weight heparin and fondaparinux, and seemed to 
depend on the sequestration of BMP6, thereby preventing the interaction with HJV and the 
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induction of hepcidin transcription. Importantly, heparin not only hampered BMP6 
dependent induction of SMAD phosphorylation and hepcidin transcription, but could also 
prevent the IL-6 and STAT3 dependent activation of hepcidin promoter, suggesting that it 
may overcome the effect of inflammation on hepcidin release also in patients with anemia of 
chronic diseases or ESRD. Due to the dose-dependent anticoagulant effects and the need for 
therapeutic monitoring, it is unlikely that unfractioned heparin could ever be implemented 
as a therapy for the anemia of chronic disease or CHD anemia in patients without 
thrombophilic conditions. However, it is conceivable that heparin could be modified 
experimentally to improve the anti-hepcidin while decreasing anticoagulant activity. This 
represents a very promising approach, because heparins with low anticoagulant, but 
preserved anti-inflammatory activity, have already been developed (Ceccarelli, Bani et al. 
2009).  
Another possibility consists in the downstream inhibition of BMP receptors. Dorsomorphin 
has been identified through a large scale in vivo screening approach as a selective inhibitor 
of BMP signaling through the antagonism of type I receptors activity (Yu, Hong et al. 2008). 
Interestingly, this small molecule compound was able to profoundly reduce basal hepcidin 
levels and increase serum iron in mice. However, due to the many roles of BMP signaling in 
the regulation of cell differentiation and homeostasis, it is likely that dorsomorphin, that for 
example effectively inhibits osteogenesis in vitro, would have unacceptable side effects in 
humans. 
Anti-cytokines Abs, such as those neutralizing IL-6, a major inducer of hepcidin during 
inflammation via STAT3 activation, would likely reduce hepcidin transcription and 
inflammation-related ESAs resistance at the same time, but potential side-effects (altered 
immune function) will be again a limiting factor for their clinical utilization. Finally, it 
should be not be forgotten that large doses of ESAs can reduce hepcidin levels, even if the 
effect seem to require the effective induction of erythropoietic activity in vivo, and is 
therefore subjected to clinical resistance, and at the price of severe side effects. 
In conclusion, the association of anti-hepcidin Abs, or possibly anti-BMP6 Abs or anti-
inflammatory/anti-hepcidin heparins, to ESAs represents the most promising approach for 
the treatment of the anemia of CHD and chronic diseases. However, as HFE has been 
demonstrated to be directly involved in the maturation of erythroid progenitors (Ramos, 
Guy et al. 2011) inflammation and atherogenesis,  it should be noted that the advantageous 
effect of the presence of HFE mutations on erythropoiesis in CHD patients may not be 
completely dependent on relatively decreased hepcidin levels (Valenti, Girelli et al. 2009). 
Therefore, even if the degree of hepcidin activity suppression achievable in vivo would likely 
play a major role in determining the clinical outcome, it is possible that anti-hepcidin 
therapies would result in a lesser improvement in anemia control than that conferred by the 
presence of protective HFE genotypes. A better comprehension of the mechanisms linking 
HFE mutations with altered protein function both related to iron sensing / hepcidin 
induction and to the direct control of cellular iron intake is needed to design new 
therapeutic approaches aimed specifically at inhibiting this molecule. Furthermore, the 
possible development of side effects, such as the promotion of carcinogenesis related to 
chronic exposure to high TSAT levels, which would confer easy access to this growth 
promoting and mutagen metal to susceptible cells in patients already exposed to high levels 
of oxidative stress, should be weighted against the potential benefits (Zacharski, Chow et al. 
2008; Dongiovanni, Fracanzani et al. 2010; Fargion, Valenti et al. 2010). 
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11. Conclusion 
Common polymorphisms in the HFE gene of HH represent a major determinant of iron 
metabolism balance in Caucasian subjects, and the subtle effect of the C282Y and H63D 
mutations is likely magnified in CHD patients by the environmental pressure determined by 
chronic inflammation, and exposure to high amounts of iron and ESAs, thereby reaching 
clinical significance. These genetic factors act by hampering hepcidin induction in 
hepatocytes in response to increased iron stores, thereby resulting in reduced serum 
hepcidin and inadequate inhibition of the activity of the iron exporter Fp-1, and 
consequently in inappropriately high duodenal iron absorption and iron recycling from 
erythrophagocytosis in macrophages and increased serum iron. As a consequence, 
homozygosity for these mutations may result in organ damage related to iron overload in 
parenchymal tissues.  
ACD and the anemia of ESRD and CHD are conversely characterized by chronic 
inflammation with increased cytokines levels, resulting in increased hepcidin levels with 
consequent reduction in iron absorption, recycling, and availability to the erythron. This 
response proves advantageous in the short-term to restrain iron availability to pathogens 
during infections, but in the case of chronicization it leads to severe anemia, and may impair 
the response to ESAs and oral and even IV iron therapy. Furthermore, as hepcidin is filtered 
by the glomerulus, ESRD itself is a contributing factor to increased hepcidin levels in CHD. 
Evidence is also accumulating that HFE mutations directly favor erythroblast maturation 
and hemoglobinization independently of serum hepcidin and reduce macrophages 
activation in response to inflammation. 
We showed that in CHD patients HFE mutations may confer an adaptive benefit by 
decreasing hepcidin release in response to iron and inflammation, thereby improving iron 
availability to erythropoiesis, anemia control, and the response to ESAs and IV iron 
therapies. This would translate in a decreased burden of side effects, mainly related to an 
increased susceptibility to cardiovascular events and infections, the latter limited to IV iron. 
Although data must be confirmed in larger prospective studies, this favorable shift in iron 
metabolism balance possibly results in reduced mortality, in particular because of 
cardiovascular and infective diseases.  
These data suggest that anti-hepcidin therapies such as anti-hepcidin or anti-BMP6 Abs, 
which are currently under development for ACD, may improve anemia management in 
CHD, concomitantly sparing the doses and side-effects of ESAs and iron and resulting in 
better quality-of-life, and most importantly a survival advantage for these patients. 
However, as the beneficial effect of HFE mutations on iron metabolism in CHD does not 
seem to be fully explained by lower hepcidin levels, direct inhibition of HFE-mediated 
regulation of iron metabolism may represent another valuable new therapeutic target. 
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